GH Research PLC

NASDAQ:GHRS

Biotechnology

Healthcare
$18.25 -0.18%

-$0.04 today

Market cap
$1.25B
Beta
1.31
P/E (TTM)
-23.8
EPS (TTM)
-$0.91
52W Low $11.32High $25.94

Volume 0.46M

Average 0.23M

GHRS Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

GH Research PLCNASDAQ: GHRS

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents broadly unchanged from a year ago

Cash & equivalents stood at $242.65M at the end of Q1 FY2026, down 0.9% from a year earlier and down 1.5% from the prior quarter. Over 3 fiscal years it compounded at +14.1% a year.

Context

  • Cash & equivalents amounted to 88.2% of total assets at the end of Q1 FY2026, up 11.7 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -0.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$242.65M-1.5% QoQ
Last fiscal yearDec 2025
$246.25M+144.3% YoY
Year agoMar 2025
$244.95M-0.9% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.9%——
1 year+144.3%——
3-year CAGR+14.1%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
246.25M USD
Year-over-year change
+144.3%
4-year CAGR
-2.9%

Cash & Equivalents vs competitors

How GHRS compares with its peers on the latest reported figures

  • GHRS's Mar 2026 cash & equivalents of $242.65M is the 4th highest of the 9 companies compared; the peer median is $239.59M.
  • Its year-over-year change of -0.9% is the lowest of 9, against a peer median of +53.8%.
  • Cash & equivalents amounts to 88.2% of total assets for GHRS, versus a peer median of 45.1%.
GHRS Competitors Peer median
Cash & Equivalents for GHRS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NERVMinerva Neurosciences, Inc.Jun 2026$24.65B +161575.2%+31.6%25.9%
LBRXLB Pharmaceuticals Inc Common StockMar 2026$320.68M +2154.3%+126.9%81.5%
ANROAlto Neuroscience, Inc.Mar 2026$263.76M +64.1%+54.0%95.5%
GHRSGH Research PLCMar 2026$242.65M -0.9%+14.1%88.2%
DFTXDefinium Therapeutics, Inc.Sep 2026$241.15M +1108.2%+22.0%22.4%
BHVNBiohaven Ltd.Jun 2026$238.03M +43.6%+3.9%64.2%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$147.07M +15.9%-8.8%95.6%
RAPPRapport Therapeutics, Inc. Common StockMar 2026$78.06M +35.5%+19.1%15.7%
MPLTMapLight Therapeutics, Inc.Mar 2026$55.71M +11.1%+19.1%13.3%
SPTXSeaport Therapeutics, Inc. Common Stock—— ———
Peer median (excluding GHRS) $239.59M+53.8%+20.5%45.1%

Competitors are the stored peer set for GHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents276.78M165.96M78.42M100.79M246.25M
Short-term Investments0083.14M48.53M34.46M
Net Receivables48K90K178K1.73M1.3M
Inventory3.01M(90K)000
Other Current Assets10K47K119K00
Total Current Assets279.84M168.54M164.09M154.23M285.98M
Property, Plant & Equipment (Net)82K97K1.07M748K620K
Goodwill00000
Intangible Assets00000
Long-term Investments085.72M61.14M33.3M0
Tax Assets00000
Other Non-current Assets00001.63M
Total Non-current Assets82K85.82M62.21M34.05M2.25M
Total Assets279.92M254.36M226.3M188.27M288.23M
Account Payables883K1.87M3.49M3.74M3.77M
Short-term Debt00343K255K0
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities168K312K6.36M8.7M407K
Total Current Liabilities2.75M4.55M6.7M8.95M8.38M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities01.87M631K369K147K
Total Liabilities2.75M4.55M7.33M9.32M8.53M
Common Stock1.3M1.3M1.3M1.3M1.55M
Retained Earnings(10.04M)(32.49M)(67.94M)(106.45M)(154.43M)
Accumulated OCI(5.54M)(10.44M)(5.86M)(7.37M)1.52M
Other Stockholders Equity00000
Minority Interest00000
Total Equity277.18M249.82M218.97M178.95M279.7M
Total Debt00974K624K512K
Net Debt(276.78M)(165.96M)(77.45M)(100.17M)(245.74M)

GH Research PLC

NASDAQ:GHRS

Intrinsic Alpha fair value

Locked

Current Price

$18.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.